Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy

Published:2017-05 Issue: Volume:253 Page:110-121
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Wu Min,Liu Xingang,Jin Weihong,Li Yongbing,Li Yang,Hu Qinglian,Chu Paul K.,Tang Guping,Ping Yuan

Funder

National Basic Research Program

City University of Hong Kong Applied Research

Hong Kong Research Grants Council

General Research Funds

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference55 articles.

1. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research;Gottesman;FEBS Lett.,2006

2. Imatinib reverses doxorubicin resistance by affecting activation of sTAT3-dependent NF-kappa B and HSP27/p38/AKT pathways and by inhibiting ABCB1;Sims;PLoS One,2013

3. Multiple molecular mechanisms for multidrug resistance transporters;Higgins;Nature,2007

4. Multidrug resistance in cancer: role of ATP-dependent transporters;Gottesman;Nat. Rev. Cancer,2002

5. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line;Meng;ACS Nano,2010

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of modules and key genes associated with breast cancer subtypes through network analysis;Scientific Reports;2024-05-29

2. Therapeutic supramolecular polymers: Designs and applications;Progress in Polymer Science;2024-01

3. Identification of modules and key genes associated with Breast Cancer subtypes through network analysis;2023-08-03

4. Development of CRISPR/Cas Delivery Systems for In Vivo Precision Genome Editing;Accounts of Chemical Research;2023-08-01

5. Comprehensive Pan-Cancer Analyses of Immunogenic Cell Death as a Biomarker in Predicting Prognosis and Therapeutic Response;Cancers;2022-12-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3